公司宣称其技术潜力已获得初步验证，三款通过计算工程技术开发的蛋白质药物已进入人体临床试验阶 段。其中进度最快的GB-0895是一款研究性长效抗胸腺基质淋巴细胞生成素单克隆抗体，目前正在重症 哮喘适应症的注册性临床三期试验中招募患者。 Generate Biomedicines计划以股票代码"GENB"于今晚在纳斯达克挂牌上市。高盛、摩根士丹利、Piper Sandler、古根海姆证券及Cantor Fitzgerald担任本次发行的联合账簿管理人。 据公司介绍，其人工智能驱动的Generate平台构建了一个紧密整合的"设计-构建-测试-学习"闭环系统， 旨在生成具有治疗价值的专有数据并开发差异化分子解决方案。 专注于免疫学与肿瘤学领域的AI药物研发公司Generate Biomedicines(GENB.US)正式公布美股IPO发行 价。这家处于临床三期阶段的生物科技公司以每股16美元(位于15至17美元定价区间中点)发行2500万 股，成功募资4亿美元。 ...

As filed with the Securities and Exchange Commission on February 23, 2026. Registration No. 333-293204 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Generate Biomedicines, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1630228 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 101 South Street, Suite 9 ...

As filed with the Securities and Exchange Commission on February 4, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Generate Biomedicines, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1630228 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 101 South Street, Suite 900 Somerville, MA 02143 (8 ...